Gyroscope Therapeutics is a clinical-stage retinal gene therapy company developing gene therapy beyond rare diseases to treat a leading cause of blindness, dry age-related macular degeneration (AMD).

Biotechnology

Gyroscope Therapeutics

Gyroscope Therapeutics' headquarters in London, United Kingdom

Khurem Farooq

Nadia Waheed

Jane Hughes

Edward Lang Jr

Jessica Stitt

Elaine Johnston

Ingrid Boyes

Keith Peters

Alberto Auricchio

Pete Coffey

Robert Maclaren

Matthew Pickering

David Steel

Timothy Stout

Jacque Duncan

Jeffrey S. Heier

Allen C. Ho

Hendrik P.N. Scholl

Bernhard H.F. Weber

Charles C. Wykoff

Sean Bohen

Arshad M. Khanani

Chris Hollowood

Ian Clark

David Kavanagh

Claire Harris

Jean Bennett

The Clinical and Scientific Operations team at Gyroscope Therapeutics is responsible for overseeing the design and execution of clinical trials related to retinal gene therapies. This multidisciplinary team collaborates closely with scientific and clinical advisory board members, researchers, and operational experts to ensure robust protocol development, regulatory compliance, and quality control in the advancement of innovative treatments for dry age-related macular degeneration. Their work is crucial in bridging laboratory research with clinical application, ultimately aiming to improve patient outcomes in vision health.

Clinical and Scientific Operations

The Research and Development team at Gyroscope Therapeutics focuses on advancing innovative gene therapies aimed at treating dry age-related macular degeneration and other retinal diseases. Comprising experts in biology, translational research, and analytical development, the team collaborates to design, develop, and optimize therapies, ensuring robust preclinical and clinical validation to bring effective treatments to patients.

Research and Development

The Leadership Team at Gyroscope Therapeutics is responsible for guiding the strategic direction of the company, overseeing clinical development, technical operations, and business strategies. They collaborate to drive innovation in retinal gene therapy, ensure operational efficiency, manage financial health, and foster a culture of talent and scientific excellence, all aimed at advancing treatments for diseases like dry AMD.

Leadership Team

The Finance and Administration team at Gyroscope Therapeutics is responsible for managing the company's financial planning, budgeting, and accounting functions. This team ensures accurate financial reporting, compliance with regulatory standards, and efficient allocation of resources to support the development of innovative gene therapies for dry AMD. They work collaboratively to analyze financial performance and provide strategic insights that drive the company's growth and operational efficiency.

Finance and Administration

Gyroscope Therapeutics

Org chart

Board & advisors

Teams

Clinical and Scientific Operations

Research and Development

Leadership Team

Finance and Administration

Offices

Gyroscope Therapeutics

Org chart

Board & advisors

Teams

Clinical and Scientific Operations

Research and Development

Leadership Team

Finance and Administration

Offices

Related companies